Inflarx (NASDAQ:IFRX) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a report released on Thursday, November 1st.
A number of other research firms also recently weighed in on IFRX. Zacks Investment Research raised Inflarx from a “sell” rating to a “hold” rating in a research note on Wednesday, July 18th. BMO Capital Markets assumed coverage on Inflarx in a research note on Friday, July 13th. They set an “outperform” rating and a $45.00 price target on the stock. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $42.67.
Shares of NASDAQ IFRX traded down $1.05 during trading on Thursday, reaching $32.45. The company had a trading volume of 5,800 shares, compared to its average volume of 43,566. Inflarx has a 12 month low of $14.47 and a 12 month high of $42.83. The firm has a market capitalization of $795.47 million and a PE ratio of -10.85.
Inflarx (NASDAQ:IFRX) last announced its earnings results on Thursday, August 9th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.24. On average, analysts forecast that Inflarx will post -1.43 earnings per share for the current year.
Several institutional investors have recently modified their holdings of IFRX. Barclays PLC bought a new position in shares of Inflarx in the first quarter valued at approximately $144,000. Matisse Capital bought a new position in shares of Inflarx in the third quarter valued at approximately $203,000. Northern Trust Corp bought a new position in shares of Inflarx in the first quarter valued at approximately $228,000. Bank of New York Mellon Corp bought a new position in shares of Inflarx in the third quarter valued at approximately $277,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Inflarx by 29.2% in the third quarter. JPMorgan Chase & Co. now owns 10,700 shares of the company’s stock valued at $367,000 after acquiring an additional 2,420 shares in the last quarter. 54.80% of the stock is owned by hedge funds and other institutional investors.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Further Reading: What does cost of debt say about a company’s financial health?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.